Ryan Fukushima Sells 41,095 Shares of Tempus AI (NASDAQ:TEM) Stock

Posted by Brian Himes on Aug 20th, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Ryan Fukushima sold 41,095 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the sale, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ryan Fukushima also recently made the following trade(s):

On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total transaction of $1,000,800.00.
On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total transaction of $1,100,153.42.
On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76.
On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00.

Tempus AI Trading Up 8.8%

Tempus AI stock traded up $5.40 during trading hours on Thursday, reaching $66.65. 20,103,049 shares of the company’s stock were exchanged, compared to its average volume of 5,600,288. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The firm’s 50 day simple moving average is $52.44 and its 200 day simple moving average is $51.21. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The firm has a market capitalization of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period last year, the company posted ($0.22) EPS. Research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at about $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI during the 4th quarter worth approximately $27,000. Harvest Fund Management Co. Ltd acquired a new position in Tempus AI during the 3rd quarter worth approximately $38,000. Danske Bank A S bought a new position in Tempus AI in the third quarter worth approximately $48,000. Finally, Sunbelt Securities Inc. bought a new position in Tempus AI in the third quarter worth approximately $52,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Guggenheim lifted their target price on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. BTIG Research lifted their price objective on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday. Finally, HC Wainwright dropped their target price on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $65.69.

Check Out Our Latest Report on TEM

Tempus AI Company Profile

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.